-
公开(公告)号:US11292794B2
公开(公告)日:2022-04-05
申请号:US16791715
申请日:2020-02-14
发明人: Hiroyuki Kouji , Kentaro Yamada , Akira Katoh , Toshimasa Ishizaki , Shigeru Matsuoka , Akira Nishizono , Tadashi Mishina , Atsushi Yoshimori
IPC分类号: C07D471/08 , C07D471/18 , A61P31/14 , A61P35/00
摘要: The present disclosure provides a compound that is useful for the treatment and prophylaxis of rabies. The present disclosure provides a compound represented by formula XXIF or formula XXIB: wherein R1, R2A, R2B, R3, and R4 are defined in the specification, a solvent, or a pharmaceutically acceptable salt thereof, use of such a compound, solvate, or pharmaceutically acceptable salt thereof for the treatment or prophylaxis of rabies and cancer, a pharmaceutical composition comprising such a compound, solvate, or pharmaceutically acceptable salt thereof, and a method for the treatment or prophylaxis of rabies and cancer using the same.
-
公开(公告)号:US20220194942A1
公开(公告)日:2022-06-23
申请号:US17679075
申请日:2022-02-23
发明人: Hiroyuki Kouji , Kentaro Yamada , Akira Katoh , Toshimasa Ishizaki , Shigeru Matsuoka , Akira Nishizono , Tadashi Mishina , Atsushi Yoshimori
IPC分类号: C07D471/18 , A61P31/14 , A61P35/00 , C07D471/08
摘要: The present disclosure provides a compound that is useful for the treatment and prophylaxis of rabies. The present disclosure provides a compound represented by formula XXIIF or formula XXIIB: wherein R1, R2A, R2B, R3, and R4 are defined in the specification, a solvent, or a pharmaceutically acceptable salt thereof, use of such a compound, solvate, or pharmaceutically acceptable salt thereof for the treatment or prophylaxis of rabies and cancer, a pharmaceutical composition comprising such a compound, solvate, or pharmaceutically acceptable salt thereof, and a method for the treatment or prophylaxis of rabies and cancer using the same.
-
公开(公告)号:US20230390296A1
公开(公告)日:2023-12-07
申请号:US18250927
申请日:2021-10-29
发明人: Motoshi HAYANO , Hiroyuki KOUJI
IPC分类号: A61K31/519 , A61K31/53 , A61K31/675 , A61P21/00
CPC分类号: A61K31/519 , A61K31/53 , A61K31/675 , A61P21/00
摘要: The present disclosure has solved problems associated with the TGF-β family or the like, which is called Myostatin/GDF-8 as a molecular mechanism and targeted by sarcopenia, by evaluating a pharmaceutical product in physiological aging models, and in particular, by evaluating an increase in muscle mass and an increase in muscle strength; and has overcome harmful effects by applying targets of diseases different from sarcopenia such as dystrophia. The present disclosure has unexpectedly found a use for an OK-1-related compound as a sarcopenia treatment method through a pathway different from that of Wnt signal (proliferation of muscle stem cells) associated with Wnt/β-catenin inhibition, and is thus provided due to the findings.
-
公开(公告)号:US20220331300A1
公开(公告)日:2022-10-20
申请号:US17596101
申请日:2020-06-03
发明人: Shigeru MATSUOKA , Akira KATOH , Tadashi MISHINA , Kentaro YAMADA , Atsushi YOSHIMORI , Toshimasa ISHIZAKI , Akira NISHIZONO , Hiroyuki KOUJI
IPC分类号: A61K31/439 , A61P31/14
摘要: The present disclosure provides compounds useful in the treatment and prevention of rabies. The present disclosure provides compounds represented by formula XXIF or XXIB [in the formulas, R1, R2A, R2B, R3, and R4 are as defined in the specification], solvates or pharmaceutically acceptable salts thereof, the use of these compounds, solvates or pharmaceutically acceptable salts thereof to treat or prevent rabies, pharmaceutical compositions including these compounds, solvates or pharmaceutically acceptable salts thereof, and a method for treating and preventing rabies using the same.
-
公开(公告)号:US20210214356A1
公开(公告)日:2021-07-15
申请号:US16791715
申请日:2020-02-14
发明人: Hiroyuki Kouji , Kentaro Yamada , Akira Kato , Toshimasa Ishizaki , Shigeru Matsuoka , Akira Nishizono , Tadashi Mishina , Atsushi Yoshimori
IPC分类号: C07D471/18 , A61P31/14 , A61P35/00
摘要: The present disclosure provides a compound that is useful for the treatment and prophylaxis of rabies. The present disclosure provides a compound represented by formula XXIF or formula XXIB: wherein R1, R2A, R2B, R3, and R4 are defined in the specification, a solvent, or a pharmaceutically acceptable salt thereof, use of such a compound, solvate, or pharmaceutically acceptable salt thereof for the treatment or prophylaxis of rabies and cancer, a pharmaceutical composition comprising such a compound, solvate, or pharmaceutically acceptable salt thereof, and a method for the treatment or prophylaxis of rabies and cancer using the same.
-
-
-
-